Mucosal vaccine delivery: A focus on the breakthrough of specific barriers
Mucosal vaccines can effectively induce an immune response at the mucosal site and form the first line of defense against microbial invasion. The induced mucosal immunity includes the proliferation of effector T cells and the production of IgG and IgA antibodies, thereby effectively blocking microbi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383522003136 |
| _version_ | 1828110748974317568 |
|---|---|
| author | Mengwen Huang Miaomiao Zhang Hongbin Zhu Xiaojiao Du Jun Wang |
| author_facet | Mengwen Huang Miaomiao Zhang Hongbin Zhu Xiaojiao Du Jun Wang |
| author_sort | Mengwen Huang |
| collection | DOAJ |
| description | Mucosal vaccines can effectively induce an immune response at the mucosal site and form the first line of defense against microbial invasion. The induced mucosal immunity includes the proliferation of effector T cells and the production of IgG and IgA antibodies, thereby effectively blocking microbial infection and transmission. However, after a long period of development, the transformation of mucosal vaccines into clinical use is still relatively slow. To date, fewer than ten mucosal vaccines have been approved. Only seven mucosal vaccines against coronavirus disease 2019 (COVID-19) are under investigation in clinical trials. A representative vaccine is the adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by Chen and coworkers, which is currently in phase III clinical trials. The reason for the limited progress of mucosal vaccines may be the complicated mucosal barriers. Therefore, this review summarizes the characteristics of mucosal barriers and highlights strategies to overcome these barriers for effective mucosal vaccine delivery. |
| first_indexed | 2024-04-11T11:23:05Z |
| format | Article |
| id | doaj.art-c58f233e9f0b45a495a4e36f9c332ca8 |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-04-11T11:23:05Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-c58f233e9f0b45a495a4e36f9c332ca82022-12-22T04:26:38ZengElsevierActa Pharmaceutica Sinica B2211-38352022-09-0112934563474Mucosal vaccine delivery: A focus on the breakthrough of specific barriersMengwen Huang0Miaomiao Zhang1Hongbin Zhu2Xiaojiao Du3Jun Wang4School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, ChinaSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, ChinaSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China; Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou 510006, ChinaSchool of Medicine, South China University of Technology, Guangzhou 510006, China; Corresponding authors.School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, China; National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, China; Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou 510006, China; Corresponding authors.Mucosal vaccines can effectively induce an immune response at the mucosal site and form the first line of defense against microbial invasion. The induced mucosal immunity includes the proliferation of effector T cells and the production of IgG and IgA antibodies, thereby effectively blocking microbial infection and transmission. However, after a long period of development, the transformation of mucosal vaccines into clinical use is still relatively slow. To date, fewer than ten mucosal vaccines have been approved. Only seven mucosal vaccines against coronavirus disease 2019 (COVID-19) are under investigation in clinical trials. A representative vaccine is the adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by Chen and coworkers, which is currently in phase III clinical trials. The reason for the limited progress of mucosal vaccines may be the complicated mucosal barriers. Therefore, this review summarizes the characteristics of mucosal barriers and highlights strategies to overcome these barriers for effective mucosal vaccine delivery.http://www.sciencedirect.com/science/article/pii/S2211383522003136Mucosal vaccineMucosal barrierMucosal immune responseVaccine deliveryNanocarriers |
| spellingShingle | Mengwen Huang Miaomiao Zhang Hongbin Zhu Xiaojiao Du Jun Wang Mucosal vaccine delivery: A focus on the breakthrough of specific barriers Acta Pharmaceutica Sinica B Mucosal vaccine Mucosal barrier Mucosal immune response Vaccine delivery Nanocarriers |
| title | Mucosal vaccine delivery: A focus on the breakthrough of specific barriers |
| title_full | Mucosal vaccine delivery: A focus on the breakthrough of specific barriers |
| title_fullStr | Mucosal vaccine delivery: A focus on the breakthrough of specific barriers |
| title_full_unstemmed | Mucosal vaccine delivery: A focus on the breakthrough of specific barriers |
| title_short | Mucosal vaccine delivery: A focus on the breakthrough of specific barriers |
| title_sort | mucosal vaccine delivery a focus on the breakthrough of specific barriers |
| topic | Mucosal vaccine Mucosal barrier Mucosal immune response Vaccine delivery Nanocarriers |
| url | http://www.sciencedirect.com/science/article/pii/S2211383522003136 |
| work_keys_str_mv | AT mengwenhuang mucosalvaccinedeliveryafocusonthebreakthroughofspecificbarriers AT miaomiaozhang mucosalvaccinedeliveryafocusonthebreakthroughofspecificbarriers AT hongbinzhu mucosalvaccinedeliveryafocusonthebreakthroughofspecificbarriers AT xiaojiaodu mucosalvaccinedeliveryafocusonthebreakthroughofspecificbarriers AT junwang mucosalvaccinedeliveryafocusonthebreakthroughofspecificbarriers |